CytomX memberikan pembaruan mengenai platform Probody dan kesehatan keuangan oleh Investing.com
CytomX Therapeutics, a leading biopharmaceutical company, provided a comprehensive update on their innovative Probody therapeutic platform and product candidates during their Fourth Quarter 2023 Financial Results Conference Call. The company highlighted significant advancements in their pipeline, including promising candidates such as CX-904 and CX-2051, as well as their strategic collaborations with industry giants like Bristol-Myers … Baca Selengkapnya